Pegylated Liposomal Doxorubicin Containing Chemotherapy in the Treatment of Older Non-Hodgkin's Lymphoma Patients
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Currently there is no one standard of care for older patients with Non-Hodgkin's Lymphoma (NHL). The study will examine the tolerability and feasibility to the combination of Cyclophosphamide, Pegylated Liposomal Doxorubicin, Vincristine, Prednisone (CDOP) plus Rituximab.
Condition | Intervention | Phase |
---|---|---|
Non-Hodgkin's Lymphoma |
Drug: CDOP plus rituximab |
Phase 2 |
Study Type: | Interventional |
Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
Official Title: | A Pilot Study of Cyclophosphamide/Pegylated Liposomal Doxorubicin/Vincristine/Prednisone (CDOP) Plus Rituximab for Treatment of Elderly Patients With Previously Untreated Non-Hodgkin's Lymphoma |
- To evaluate the feasibility and tolerability of CDOP plus rituximab in elderly patients with previously untreated NHL.
- Tumor response
- duration of response
- median time to disease progression
- overall survival
Estimated Enrollment: | 50 |
Study Start Date: | March 2005 |
Study Completion Date: | September 2006 |
Elderly NHL patients tend to tolerate the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) less well when compared to the younger population. Cardiotoxicity, as well as neutropenia, are the most common side effects in the elderly population with age being a risk factor for doxorubicin induced cardiac toxicity. Treatment related toxicity in the older population can preclude adequate therapy and potentially contribute to poor outcomes. Pegylated liposomal doxorubicin has shown similar efficacy with a significant lower incidence of cardiotoxicity ad significantly fewer cardiac events compared with conventional doxorubicin. Exploration of alternative regimens to maximize tolerability and thus enhance overall efficacy in this population is warranted. Both safety and efficacy will be evaluated.
Ages Eligible for Study: | 65 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age 65 years and older;
- Diagnosis of Non-Hodgkin's lymphoma where therapy with CHOP plus rituximab is considered;
- Previously untreated;
- ECOG 0-2
- Adequate renal and hepatic functions;
- Cardiac ejection fraction at least 50% by MUGA. No significant cardiac abnormalities by EKG;
- Signed informed consent
Exclusion Criteria:
- CNS involvement by lymphoma;
- Hypersensitivity to study drugs;
- Active infection;
- Prior treatment with monoclonal antibodies for cancer;
- History of cardiac disease with New York Heart Association Class II or greater or clinical evidence of congestive heart failure
United States, California | |
Oxnard, California, United States, 93030 | |
United States, District of Columbia | |
Washington, District of Columbia, United States, 20007 | |
United States, Florida | |
Inverness, Florida, United States, 34452 | |
Lecanto, Florida, United States, 34461 | |
United States, New Jersey | |
Belleville, New Jersey, United States, 07109 |
Study Chair: | Lodovico Balducci, MD | Geriatric Oncology Consortium |
No publications provided
ClinicalTrials.gov Identifier: | NCT00120198 History of Changes |
Other Study ID Numbers: | GOC-LY-010 |
Study First Received: | July 8, 2005 |
Last Updated: | November 15, 2007 |
Health Authority: | United States: Institutional Review Board |
Keywords provided by Geriatric Oncology Consortium:
NHL elderly |
Additional relevant MeSH terms:
Lymphoma Lymphoma, Non-Hodgkin Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Doxorubicin |
Rituximab Antibiotics, Antineoplastic Antineoplastic Agents Therapeutic Uses Pharmacologic Actions Immunologic Factors Physiological Effects of Drugs Antirheumatic Agents |
ClinicalTrials.gov processed this record on October 16, 2012